Sutro Biopharma (STRO) is a post-restructuring biotech whose only clinical asset, STRO-004, is the lone clinical-stage exatecan TF-ADC globally. The stock is +328% trailing twelve months on a Navigator-style accumulation around the mid-2026 Phase 1 readout. The Q1 2026 10-Q filed May 14 contains one specific line that, paired with this week's sell-side upgrades, points to a discrete mispricing on a discrete event.

What the filing says

Cash: $202.6M (cash + marketable securities) at March 31. The February 2026 underwritten offering raised $110M gross at $13.98/share. Normalized monthly burn ≈$11.7M after stripping a one-time $7.1M Vaxcyte tech transfer settlement. Runway: management states "at least 12 months" (May 2027+); reconstruction extends to ~August 2027.

Pipeline: STRO-004 dose level 3 cohort initiated February 2026. STRO-006 (ITGβ6 ADC) IND "possible in 2026." STRO-227 (PTK7 dual-payload, tubulin + topo1i) IND "late 2026." Astellas iADC ASP2998 dosed first patient — $10M Phase 1 milestone earned Q1, received April.

The line that matters, from MD&A: STRO expects to report initial preliminary data, including "safety and pharmacokinetic data" from this trial in mid-2026. Efficacy language is deliberately absent. NHP tolerability was 50 mg/kg HNSTD; the first three dose escalation cohorts are almost certainly sub-therapeutic.

Restructuring is substantially complete. Severance liability collapsed from $2.85M to $437K. R&D −29% YoY, G&A −43% YoY. ATM facility was terminated March 23. Five of six historical collaborators have departed (Merck, BMS, EMD Serono, Ipsen, Vaxcyte); only Astellas remains active.

What the market thinks

Momentum is +23.5% one-month, +328% trailing twelve months. Sell-side stack is now $41-60, with Wedbush double-upgrading to Outperform $60 on May 15 — the trading day immediately after the 10-Q. Options open interest remains effectively dormant.

Working backward from the average $50 sell-side target implies P(confirmed objective response at mid-2026 readout) ≈ 35-40%. Our factor scenario (180d horizon) prices that state at 15%, with safety/PK-only at 55%, tolerability concern 22%, trial halt 8%. Expected return at the dominant factor: +10.1% / 180d. Sell-side implied: roughly +25%.

The gap is one number on one state: −20 to −25 percentage points on the response state. Everything else clears.

Why the gap exists

The 10-Q phrasing is buried in MD&A. Sell-side updated price targets within a trading day of filing — fast enough that nobody re-modeled the readout scope. AACR April delivered preclinical breadth but no clinical data; the response question was deferred, not answered, and the tape interpreted that as confirmation of the bull case rather than a four-month delay in the verdict. Insider buying clustered at $0.80 and ≈$21 in Q4 2025 / Q1 2026 has gone silent for 75 days at current prices — they were aggressive at lower prices and they are not pressing here. There is no options chain to price the binary, so the catalyst is being expressed entirely through equity flow and analyst ratings.

Risks (ranked)

1. Response state actually hits (15%). Stock re-rates +50-150%. Mitigated by keeping size on, not by avoiding the name.
2. Dose-limiting toxicity in DL3-4 (22%). Exatecan class has known myelosuppression. Stock −25 to −45%.
3. Trial halt / treatment-related SAE (8%). Stock −50 to −75%. Asymmetric but low base rate given NHP safety profile.
4. Sector beta drain (idio is 84%, sector loading ≈10%). XBI breaking the 200DMA drains liquidity from non-revenue biotech.
5. Astellas option non-exercise on second program. Reduces partnership option value by ≈$50M NPV.

Catalysts

• Jun-Aug 2026: STRO-004 mid-2026 Phase 1 readout (safety + PK). Dominant.
• H2 2026: STRO-006 IND submission (≈50%).
• Q4 2026: STRO-227 IND submission (≈45%).
• H2 2026 / H1 2027: DL4-DL6 dose escalation — where doses actually enter therapeutic range.
• Any time: Astellas iADC pipeline milestone (each ≈$5-15M cash).

What would change our mind

• 8-K from STRO between now and readout that adds "preliminary anti-tumor activity" to the readout scope. Mgmt has confidence DL3-4 will show signal.
• Insider open-market purchase (Form 4 code P) above $40. Officers seeing internal data and pressing.
• Astellas exercises option on second program / pays milestone > $15M.
• Pullback to $26-32 range — re-establishes margin of safety; different problem.

Evidence

LR signal: 0.75. The memo is bearish on the current price relative to fundamentals on a discrete catalyst-pricing question. It is not a thesis kill — the company is intact, cash extends well past the catalyst, the platform is real. Sell-side upgraded into the explicit absence of efficacy in management's readout scope, and the −20-25pp gap on the response state is large enough to represent a meaningful overestimate of near-term catalyst scope.